{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,13]],"date-time":"2026-07-13T11:11:10Z","timestamp":1783941070885,"version":"3.55.0"},"reference-count":143,"publisher":"Elsevier BV","issue":"5","license":[{"start":{"date-parts":[[2024,9,1]],"date-time":"2024-09-01T00:00:00Z","timestamp":1725148800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2024,9,1]],"date-time":"2024-09-01T00:00:00Z","timestamp":1725148800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2024,6,26]],"date-time":"2024-06-26T00:00:00Z","timestamp":1719360000000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/501100004731","name":"Zhejiang Province Natural Science Foundation","doi-asserted-by":"publisher","award":["LY22H160037"],"award-info":[{"award-number":["LY22H160037"]}],"id":[{"id":"10.13039\/501100004731","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100001809","name":"National Natural Science Foundation of China","doi-asserted-by":"publisher","award":["81972718"],"award-info":[{"award-number":["81972718"]}],"id":[{"id":"10.13039\/501100001809","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Biochimica et Biophysica Acta (BBA) - Reviews on Cancer"],"published-print":{"date-parts":[[2024,9]]},"DOI":"10.1016\/j.bbcan.2024.189145","type":"journal-article","created":{"date-parts":[[2024,6,26]],"date-time":"2024-06-26T15:50:49Z","timestamp":1719417049000},"page":"189145","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":6,"title":["Evolving treatment landscape in thymic epithelial tumors: From mechanism to therapy"],"prefix":"10.1016","volume":"1879","author":[{"given":"Yehao","family":"Yang","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ying","family":"Yu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yun","family":"Fan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hui","family":"Li","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"2","key":"10.1016\/j.bbcan.2024.189145_bb0005","doi-asserted-by":"crossref","first-page":"367","DOI":"10.1097\/JTO.0000000000000393","article-title":"The impact of thymoma histotype on prognosis in a worldwide database","volume":"10","author":"Weis","year":"2015","journal-title":"J. Thorac. Oncol."},{"issue":"10 Suppl 4","key":"10.1016\/j.bbcan.2024.189145_bb0010","doi-asserted-by":"crossref","first-page":"S304","DOI":"10.1097\/JTO.0b013e3181f20c05","article-title":"Staging system of thymoma","volume":"5","author":"Masaoka","year":"2010","journal-title":"J. Thorac. Oncol."},{"issue":"1","key":"10.1016\/j.bbcan.2024.189145_bb0015","doi-asserted-by":"crossref","first-page":"299","DOI":"10.1016\/j.athoracsur.2012.09.006","article-title":"Thymic carcinoma: a multivariate analysis of factors predictive of survival in 290 patients","volume":"95","author":"Weksler","year":"2013","journal-title":"Ann. Thorac. Surg."},{"issue":"3","key":"10.1016\/j.bbcan.2024.189145_bb0020","doi-asserted-by":"crossref","first-page":"299","DOI":"10.1016\/j.jtho.2022.10.016","article-title":"Surgical, radiation, and systemic treatments of patients with Thymic epithelial tumors: a systematic review","volume":"18","author":"Falkson","year":"2023","journal-title":"J. Thorac. Oncol."},{"issue":"2","key":"10.1016\/j.bbcan.2024.189145_bb0025","doi-asserted-by":"crossref","first-page":"200","DOI":"10.1016\/j.jtho.2021.10.010","article-title":"The 2021 WHO classification of tumors of the Thymus and mediastinum: what is new in Thymic epithelial, germ cell, and mesenchymal tumors?","volume":"17","author":"Marx","year":"2022","journal-title":"J. Thorac. Oncol."},{"issue":"10","key":"10.1016\/j.bbcan.2024.189145_bb0030","doi-asserted-by":"crossref","first-page":"1383","DOI":"10.1097\/JTO.0000000000000654","article-title":"The 2015 World Health Organization classification of tumors of the Thymus: continuity and changes","volume":"10","author":"Marx","year":"2015","journal-title":"J. Thorac. Oncol."},{"issue":"2","key":"10.1016\/j.bbcan.2024.189145_bb0035","doi-asserted-by":"crossref","first-page":"105","DOI":"10.1159\/000472255","article-title":"Thymic neuroendocrine neoplasms: biological behaviour and therapy","volume":"105","author":"Jia","year":"2017","journal-title":"Neuroendocrinology"},{"issue":"1","key":"10.1016\/j.bbcan.2024.189145_bb0040","doi-asserted-by":"crossref","first-page":"95","DOI":"10.1016\/j.jtcvs.2014.09.124","article-title":"Thymic carcinoma outcomes and prognosis: results of an international analysis","volume":"149","author":"Ahmad","year":"2015","journal-title":"J. Thorac. Cardiovasc. Surg."},{"issue":"6","key":"10.1016\/j.bbcan.2024.189145_bb0045","doi-asserted-by":"crossref","first-page":"1117","DOI":"10.1097\/SLA.0b013e3181dd4ec4","article-title":"Thymic neuroendocrine tumors: a SEER database analysis of 160 patients","volume":"251","author":"Gaur","year":"2010","journal-title":"Ann. Surg."},{"issue":"12","key":"10.1016\/j.bbcan.2024.189145_bb0050","doi-asserted-by":"crossref","first-page":"1810","DOI":"10.1097\/JTO.0000000000000363","article-title":"Clinical characteristics and outcomes for patients with thymic carcinoma: evaluation of Masaoka staging","volume":"9","author":"Litvak","year":"2014","journal-title":"J. Thorac. Oncol."},{"issue":"Suppl. 5","key":"10.1016\/j.bbcan.2024.189145_bb0055","doi-asserted-by":"crossref","first-page":"v40","DOI":"10.1093\/annonc\/mdv277","article-title":"Thymic epithelial tumours: ESMO clinical practice guidelines for diagnosis, treatment and follow-up","volume":"26","author":"Girard","year":"2015","journal-title":"Ann. Oncol."},{"issue":"3","key":"10.1016\/j.bbcan.2024.189145_bb0060","doi-asserted-by":"crossref","first-page":"878","DOI":"10.1016\/S0003-4975(03)00555-1","article-title":"Therapy for thymic epithelial tumors: a clinical study of 1,320 patients from Japan","volume":"76","author":"Kondo","year":"2003","journal-title":"Ann. Thorac. Surg."},{"issue":"11","key":"10.1016\/j.bbcan.2024.189145_bb0065","doi-asserted-by":"crossref","first-page":"1258","DOI":"10.1016\/j.jtho.2022.08.007","article-title":"Surgical, radiation, and systemic treatments of patients with Thymic epithelial tumors: a clinical practice guideline","volume":"17","author":"Falkson","year":"2022","journal-title":"J. Thorac. Oncol."},{"issue":"5","key":"10.1016\/j.bbcan.2024.189145_bb0070","doi-asserted-by":"crossref","first-page":"637","DOI":"10.1016\/j.jtho.2022.01.021","article-title":"Thymic carcinomas-a concise multidisciplinary update on recent developments from the Thymic carcinoma working group of the international Thymic malignancy interest group","volume":"17","author":"Roden","year":"2022","journal-title":"J. Thorac. Oncol."},{"issue":"2","key":"10.1016\/j.bbcan.2024.189145_bb0075","doi-asserted-by":"crossref","first-page":"244","DOI":"10.1016\/j.ccell.2018.01.003","article-title":"The integrated genomic landscape of Thymic epithelial tumors","volume":"33","author":"Radovich","year":"2018","journal-title":"Cancer Cell"},{"issue":"7","key":"10.1016\/j.bbcan.2024.189145_bb0080","doi-asserted-by":"crossref","DOI":"10.3390\/ijms23074045","article-title":"Thymic epithelial neoplasms: focusing on the epigenetic alterations","volume":"23","author":"Psilopatis","year":"2022","journal-title":"Int. J. Mol. Sci."},{"issue":"16","key":"10.1016\/j.bbcan.2024.189145_bb0085","doi-asserted-by":"crossref","first-page":"4855","DOI":"10.1158\/1078-0432.CCR-17-0066","article-title":"Genomic analysis of Thymic epithelial tumors identifies novel subtypes associated with distinct clinical features","volume":"23","author":"Lee","year":"2017","journal-title":"Clin. Cancer Res."},{"issue":"1","key":"10.1016\/j.bbcan.2024.189145_bb0090","doi-asserted-by":"crossref","first-page":"70","DOI":"10.1186\/s12943-023-01772-4","article-title":"Immunotherapy of thymic epithelial tumors: molecular understandings and clinical perspectives","volume":"22","author":"Ao","year":"2023","journal-title":"Mol. Cancer"},{"issue":"14","key":"10.1016\/j.bbcan.2024.189145_bb0095","doi-asserted-by":"crossref","DOI":"10.3390\/ijms23147864","article-title":"Unraveling the immune microenvironment of Thymic epithelial tumors: implications for autoimmunity and treatment","volume":"23","author":"Masaoutis","year":"2022","journal-title":"Int. J. Mol. Sci."},{"key":"10.1016\/j.bbcan.2024.189145_bb0100","doi-asserted-by":"crossref","DOI":"10.1016\/j.ctrv.2020.102014","article-title":"Thymic epithelial tumors: from biology to treatment","volume":"86","author":"Conforti","year":"2020","journal-title":"Cancer Treat. Rev."},{"issue":"8","key":"10.1016\/j.bbcan.2024.189145_bb0105","doi-asserted-by":"crossref","first-page":"1070","DOI":"10.1016\/j.jtho.2023.04.009","article-title":"STYLE (NCT03449173): a phase 2 trial of Sunitinib in patients with type B3 Thymoma or Thymic carcinoma in second and further lines","volume":"18","author":"Proto","year":"2023","journal-title":"J. Thorac. Oncol."},{"issue":"6","key":"10.1016\/j.bbcan.2024.189145_bb0110","doi-asserted-by":"crossref","first-page":"843","DOI":"10.1016\/S1470-2045(20)30162-5","article-title":"Lenvatinib in patients with advanced or metastatic thymic carcinoma (REMORA): a multicentre, phase 2 trial","volume":"21","author":"Sato","year":"2020","journal-title":"Lancet Oncol."},{"issue":"10","key":"10.1016\/j.bbcan.2024.189145_bb0115","doi-asserted-by":"crossref","first-page":"1287","DOI":"10.1016\/S1470-2045(22)00542-3","article-title":"Avelumab plus axitinib in unresectable or metastatic type B3 thymomas and thymic carcinomas (CAVEATT): a single-arm, multicentre, phase 2 trial","volume":"23","author":"Conforti","year":"2022","journal-title":"Lancet Oncol."},{"issue":"23","key":"10.1016\/j.bbcan.2024.189145_bb0120","doi-asserted-by":"crossref","DOI":"10.3390\/ijms242317065","article-title":"An overview of the use of anti-Angiogenic agents in the treatment of Thymic epithelial tumors","volume":"24","author":"Agrafiotis","year":"2023","journal-title":"Int. J. Mol. Sci."},{"issue":"23","key":"10.1016\/j.bbcan.2024.189145_bb0125","doi-asserted-by":"crossref","DOI":"10.3390\/cancers15235574","article-title":"Thymic epithelial tumor and immune system: the role of immunotherapy","volume":"15","author":"Perrino","year":"2023","journal-title":"Cancers (Basel)"},{"issue":"2","key":"10.1016\/j.bbcan.2024.189145_bb0130","doi-asserted-by":"crossref","first-page":"131","DOI":"10.1053\/j.semdp.2021.06.011","article-title":"Molecular landscape of thymic epithelial tumors","volume":"39","author":"Prays","year":"2022","journal-title":"Semin. Diagn. Pathol."},{"issue":"4","key":"10.1016\/j.bbcan.2024.189145_bb0135","doi-asserted-by":"crossref","first-page":"477","DOI":"10.1038\/bjc.2015.425","article-title":"A large microRNA cluster on chromosome 19 is a transcriptional hallmark of WHO type a and AB thymomas","volume":"114","author":"Radovich","year":"2016","journal-title":"Br. J. Cancer"},{"issue":"1","key":"10.1016\/j.bbcan.2024.189145_bb0140","doi-asserted-by":"crossref","first-page":"196","DOI":"10.1111\/his.15097","article-title":"Thymic epithelial tumours: histopathological classification and differential diagnosis","volume":"84","author":"von der Thusen","year":"2024","journal-title":"Histopathology"},{"issue":"9","key":"10.1016\/j.bbcan.2024.189145_bb0145","doi-asserted-by":"crossref","first-page":"2409","DOI":"10.1093\/annonc\/mdr626","article-title":"Activating c-KIT mutations in a subset of thymic carcinoma and response to different c-KIT inhibitors","volume":"23","author":"Schirosi","year":"2012","journal-title":"Ann. Oncol."},{"issue":"3","key":"10.1016\/j.bbcan.2024.189145_bb0150","doi-asserted-by":"crossref","first-page":"551","DOI":"10.1007\/s12253-016-0144-8","article-title":"Molecular profiling of Thymoma and Thymic carcinoma: genetic differences and potential novel therapeutic targets","volume":"23","author":"Enkner","year":"2017","journal-title":"Pathol. Oncol. Res."},{"key":"10.1016\/j.bbcan.2024.189145_bb0155","doi-asserted-by":"crossref","first-page":"24","DOI":"10.1016\/j.lungcan.2016.12.005","article-title":"Analysis of a panel of druggable gene mutations and of ALK and PD-L1 expression in a series of thymic epithelial tumors (TETs)","volume":"104","author":"Tiseo","year":"2017","journal-title":"Lung Cancer"},{"issue":"5","key":"10.1016\/j.bbcan.2024.189145_bb0160","doi-asserted-by":"crossref","DOI":"10.1016\/j.esmoop.2023.101627","article-title":"Genomic characterization of thymic epithelial tumors in a real-world dataset","volume":"8","author":"Kurokawa","year":"2023","journal-title":"ESMO Open."},{"key":"10.1016\/j.bbcan.2024.189145_bb0165","doi-asserted-by":"crossref","first-page":"1264325","DOI":"10.3389\/fimmu.2023.1264325","article-title":"Unraveling molecular networks in thymic epithelial tumors: deciphering the unique signatures","volume":"14","author":"Zhang","year":"2023","journal-title":"Front. Immunol."},{"issue":"2","key":"10.1016\/j.bbcan.2024.189145_bb0170","doi-asserted-by":"crossref","first-page":"165","DOI":"10.1046\/j.1365-2559.2003.01663.x","article-title":"Expression of apoptosis-related markers and HER-2\/neu in thymic epithelial tumours","volume":"43","author":"Pan","year":"2003","journal-title":"Histopathology"},{"issue":"1","key":"10.1016\/j.bbcan.2024.189145_bb0175","doi-asserted-by":"crossref","first-page":"101","DOI":"10.1007\/s00428-021-03068-8","article-title":"Molecular pathology of thymomas: implications for diagnosis and therapy","volume":"478","author":"Marx","year":"2021","journal-title":"Virchows Arch."},{"issue":"4","key":"10.1016\/j.bbcan.2024.189145_bb0180","doi-asserted-by":"crossref","first-page":"560","DOI":"10.1038\/s41379-019-0382-x","article-title":"Metaplastic thymoma: a distinctive thymic neoplasm characterized by YAP1-MAML2 gene fusions","volume":"33","author":"Vivero","year":"2020","journal-title":"Mod. Pathol."},{"issue":"8","key":"10.1016\/j.bbcan.2024.189145_bb0185","doi-asserted-by":"crossref","first-page":"1345","DOI":"10.1016\/j.jtho.2016.04.013","article-title":"PI3K as a potential therapeutic target in Thymic epithelial tumors","volume":"11","author":"Alberobello","year":"2016","journal-title":"J. Thorac. Oncol."},{"issue":"9","key":"10.1016\/j.bbcan.2024.189145_bb0190","doi-asserted-by":"crossref","first-page":"1447","DOI":"10.1097\/JTO.0b013e3181e96e30","article-title":"Expression and mutational status of c-kit in thymic epithelial tumors","volume":"5","author":"Petrini","year":"2010","journal-title":"J. Thorac. Oncol."},{"issue":"25","key":"10.1016\/j.bbcan.2024.189145_bb0195","doi-asserted-by":"crossref","first-page":"2625","DOI":"10.1056\/NEJM200406173502523","article-title":"Thymic carcinoma with overexpression of mutated KIT and the response to imatinib","volume":"350","author":"Str\u00f6bel","year":"2004","journal-title":"N. Engl. J. Med."},{"issue":"4","key":"10.1016\/j.bbcan.2024.189145_bb0200","doi-asserted-by":"crossref","first-page":"527","DOI":"10.3892\/mco.2016.752","article-title":"C-kit mutation-positive advanced thymic carcinoma successfully treated as a mediastinal gastrointestinal stromal tumor: a case report","volume":"4","author":"Hirai","year":"2016","journal-title":"Mol. Clin. Oncol."},{"issue":"33","key":"10.1016\/j.bbcan.2024.189145_bb0205","doi-asserted-by":"crossref","first-page":"e803","DOI":"10.1200\/JCO.2011.36.6427","article-title":"Impressive response with imatinib in a heavily pretreated patient with metastatic c-KIT mutated thymic carcinoma","volume":"29","author":"Buti","year":"2011","journal-title":"J. Clin. Oncol."},{"issue":"10","key":"10.1016\/j.bbcan.2024.189145_bb0210","doi-asserted-by":"crossref","first-page":"1270","DOI":"10.1097\/JTO.0b013e3181b6be57","article-title":"Imatinib mesylate in patients with WHO B3 thymomas and thymic carcinomas","volume":"4","author":"Giaccone","year":"2009","journal-title":"J. Thorac. Oncol."},{"issue":"15_suppl","key":"10.1016\/j.bbcan.2024.189145_bb0215","doi-asserted-by":"crossref","first-page":"8116","DOI":"10.1200\/jco.2008.26.15_suppl.8116","article-title":"Imatinib for the treatment of thymic carcinoma","volume":"26","author":"Salter","year":"2008","journal-title":"J. Clin. Oncol."},{"issue":"3","key":"10.1016\/j.bbcan.2024.189145_bb0220","doi-asserted-by":"crossref","first-page":"316","DOI":"10.1016\/j.lungcan.2008.03.013","article-title":"Mutational status of EGFR and KIT in thymoma and thymic carcinoma","volume":"62","author":"Yoh","year":"2008","journal-title":"Lung Cancer"},{"issue":"6","key":"10.1016\/j.bbcan.2024.189145_bb0225","doi-asserted-by":"crossref","first-page":"351","DOI":"10.1093\/jjco\/hyl028","article-title":"Expression and mutation statuses of epidermal growth factor receptor in thymic epithelial tumors","volume":"36","author":"Suzuki","year":"2006","journal-title":"Jpn. J. Clin. Oncol."},{"issue":"2","key":"10.1016\/j.bbcan.2024.189145_bb0230","doi-asserted-by":"crossref","first-page":"261","DOI":"10.1016\/j.lungcan.2006.01.009","article-title":"Thymic carcinoma with epidermal growth factor receptor gene mutations","volume":"52","author":"Yamaguchi","year":"2006","journal-title":"Lung Cancer"},{"issue":"15_suppl","key":"10.1016\/j.bbcan.2024.189145_bb0235","doi-asserted-by":"crossref","first-page":"19087","DOI":"10.1200\/jco.2008.26.15_suppl.19087","article-title":"A phase II trial of erlotinib plus bevacizumab in patients with recurrent thymoma or thymic carcinoma","volume":"26","author":"Bedano","year":"2008","journal-title":"J. Clin. Oncol."},{"issue":"16_suppl","key":"10.1016\/j.bbcan.2024.189145_bb0240","doi-asserted-by":"crossref","first-page":"7068","DOI":"10.1200\/jco.2005.23.16_suppl.7068","article-title":"Phase II study of gefitinib treatment in advanced thymic malignancies","volume":"23","author":"Kurup","year":"2005","journal-title":"J. Clin. Oncol."},{"issue":"9","key":"10.1016\/j.bbcan.2024.189145_bb0245","doi-asserted-by":"crossref","first-page":"1439","DOI":"10.1097\/JTO.0b013e3181e392a8","article-title":"Insulin-like growth factor-1 receptor expression in thymic malignancies","volume":"5","author":"Girard","year":"2010","journal-title":"J. Thorac. Oncol."},{"issue":"20","key":"10.1016\/j.bbcan.2024.189145_bb0250","doi-asserted-by":"crossref","first-page":"4686","DOI":"10.1002\/cncr.25367","article-title":"Insulin-like growth factor-1 receptor and phosphorylated AKT-serine 473 expression in 132 resected thymomas and thymic carcinomas","volume":"116","author":"Zucali","year":"2010","journal-title":"Cancer"},{"issue":"2","key":"10.1016\/j.bbcan.2024.189145_bb0255","doi-asserted-by":"crossref","first-page":"191","DOI":"10.1016\/S1470-2045(13)70596-5","article-title":"Cixutumumab for patients with recurrent or refractory advanced thymic epithelial tumours: a multicentre, open-label, phase 2 trial","volume":"15","author":"Rajan","year":"2014","journal-title":"Lancet Oncol."},{"issue":"1","key":"10.1016\/j.bbcan.2024.189145_bb0260","doi-asserted-by":"crossref","first-page":"220","DOI":"10.1378\/chest.08-2482","article-title":"Apoptosis-related (survivin, Bcl-2), tumor suppressor gene (p53), proliferation (Ki-67), and non-receptor tyrosine kinase (Src) markers expression and correlation with clinicopathologic variables in 60 thymic neoplasms","volume":"136","author":"Khoury","year":"2009","journal-title":"Chest"},{"issue":"1","key":"10.1016\/j.bbcan.2024.189145_bb0265","doi-asserted-by":"crossref","first-page":"57","DOI":"10.1016\/j.lungcan.2015.04.008","article-title":"A phase II study of saracatinib (AZD0530), a Src inhibitor, administered orally daily to patients with advanced thymic malignancies","volume":"89","author":"Gubens","year":"2015","journal-title":"Lung Cancer"},{"issue":"6","key":"10.1016\/j.bbcan.2024.189145_bb0270","doi-asserted-by":"crossref","first-page":"1065","DOI":"10.1007\/s00280-008-0699-5","article-title":"Identification and validation of phospho-SRC, a novel and potential pharmacodynamic biomarker for dasatinib (SPRYCEL), a multi-targeted kinase inhibitor","volume":"62","author":"Luo","year":"2008","journal-title":"Cancer Chemother. Pharmacol."},{"issue":"4","key":"10.1016\/j.bbcan.2024.189145_bb0275","doi-asserted-by":"crossref","first-page":"342","DOI":"10.1200\/JCO.2017.74.4078","article-title":"Phase II study of Everolimus in patients with Thymoma and Thymic carcinoma previously treated with cisplatin-based chemotherapy","volume":"36","author":"Zucali","year":"2018","journal-title":"J. Clin. Oncol."},{"key":"10.1016\/j.bbcan.2024.189145_bb0280","doi-asserted-by":"crossref","DOI":"10.3389\/fonc.2022.891383","article-title":"A phase II study of buparlisib in relapsed or refractory thymomas","volume":"12","author":"Abu Zaid","year":"2022","journal-title":"Front. Oncol."},{"issue":"2","key":"10.1016\/j.bbcan.2024.189145_bb0285","doi-asserted-by":"crossref","first-page":"223","DOI":"10.1016\/j.jtho.2022.10.008","article-title":"A phase 2 study of Palbociclib for recurrent or refractory advanced Thymic epithelial tumors (KCSG LU17-21)","volume":"18","author":"Jung","year":"2023","journal-title":"J. Thorac. Oncol."},{"issue":"7","key":"10.1016\/j.bbcan.2024.189145_bb0290","doi-asserted-by":"crossref","DOI":"10.1038\/cddis.2012.92","article-title":"Copy number aberrations of BCL2 and CDKN2A\/B identified by array-CGH in thymic epithelial tumors","volume":"3","author":"Petrini","year":"2012","journal-title":"Cell Death Dis."},{"issue":"15_suppl","key":"10.1016\/j.bbcan.2024.189145_bb0295","doi-asserted-by":"crossref","first-page":"8519","DOI":"10.1200\/JCO.2018.36.15_suppl.8519","article-title":"Efficacy of milciclib (PHA-848125AC), a pan-cyclin d-dependent kinase inhibitor, in two phase II studies with thymic carcinoma (TC) and B3 thymoma (B3T) patients","volume":"36","author":"Besse","year":"2018","journal-title":"J. Clin. Oncol."},{"key":"10.1016\/j.bbcan.2024.189145_bb0300","doi-asserted-by":"crossref","first-page":"7336","DOI":"10.1038\/srep07336","article-title":"Mutations of epigenetic regulatory genes are common in thymic carcinomas","volume":"4","author":"Wang","year":"2014","journal-title":"Sci. Rep."},{"issue":"15","key":"10.1016\/j.bbcan.2024.189145_bb0305","doi-asserted-by":"crossref","first-page":"2052","DOI":"10.1200\/JCO.2010.32.4467","article-title":"Phase II study of belinostat in patients with recurrent or refractory advanced thymic epithelial tumors","volume":"29","author":"Giaccone","year":"2011","journal-title":"J. Clin. Oncol."},{"issue":"21","key":"10.1016\/j.bbcan.2024.189145_bb0310","doi-asserted-by":"crossref","first-page":"5392","DOI":"10.1158\/1078-0432.CCR-14-0968","article-title":"A phase I\/II trial of belinostat in combination with cisplatin, doxorubicin, and cyclophosphamide in thymic epithelial tumors: a clinical and translational study","volume":"20","author":"Thomas","year":"2014","journal-title":"Clin. Cancer Res."},{"issue":"13","key":"10.1016\/j.bbcan.2024.189145_bb0315","doi-asserted-by":"crossref","first-page":"3902","DOI":"10.1158\/1078-0432.CCR-05-2376","article-title":"MECT1-MAML2 fusion transcript defines a favorable subset of mucoepidermoid carcinoma","volume":"12","author":"Okabe","year":"2006","journal-title":"Clin. Cancer Res."},{"key":"10.1016\/j.bbcan.2024.189145_bb0320","first-page":"1","article-title":"Development and function of cortical thymic epithelial cells","volume":"373","author":"Takada","year":"2014","journal-title":"Curr. Top. Microbiol. Immunol."},{"key":"10.1016\/j.bbcan.2024.189145_bb0325","first-page":"19","article-title":"Mechanisms of thymus medulla development and function","volume":"373","author":"Anderson","year":"2014","journal-title":"Curr. Top. Microbiol. Immunol."},{"issue":"3","key":"10.1016\/j.bbcan.2024.189145_bb0330","doi-asserted-by":"crossref","DOI":"10.1016\/j.bbcan.2022.188730","article-title":"Recent thymic emigrants as the bridge between thymoma and autoimmune diseases","volume":"1877","author":"Ao","year":"2022","journal-title":"Biochim. Biophys. Acta Rev. Cancer"},{"issue":"9 Suppl 2","key":"10.1016\/j.bbcan.2024.189145_bb0335","doi-asserted-by":"crossref","first-page":"S137","DOI":"10.1097\/JTO.0000000000000299","article-title":"Alterations of the immune system in thymic malignancies","volume":"9","author":"Weksler","year":"2014","journal-title":"J. Thorac. Oncol."},{"issue":"1","key":"10.1016\/j.bbcan.2024.189145_bb0340","doi-asserted-by":"crossref","first-page":"5463","DOI":"10.1038\/s41467-022-33170-7","article-title":"The immune landscape of human thymic epithelial tumors","volume":"13","author":"Xin","year":"2022","journal-title":"Nat. Commun."},{"issue":"4","key":"10.1016\/j.bbcan.2024.189145_bb0345","first-page":"1198","article-title":"Classification, histopathology and molecular pathology of thymic epithelial tumors: a review","volume":"26","author":"Valavanis","year":"2021","journal-title":"J. BUON"},{"issue":"10 Suppl 4","key":"10.1016\/j.bbcan.2024.189145_bb0350","doi-asserted-by":"crossref","first-page":"S266","DOI":"10.1097\/JTO.0b013e3181f1f63f","article-title":"The autoimmune regulator AIRE in thymoma biology: autoimmunity and beyond","volume":"5","author":"Marx","year":"2010","journal-title":"J. Thorac. Oncol."},{"issue":"23","key":"10.1016\/j.bbcan.2024.189145_bb0355","doi-asserted-by":"crossref","first-page":"4848","DOI":"10.1182\/blood-2010-05-286161","article-title":"Anti-cytokine autoantibodies are associated with opportunistic infection in patients with thymic neoplasia","volume":"116","author":"Burbelo","year":"2010","journal-title":"Blood"},{"issue":"9","key":"10.1016\/j.bbcan.2024.189145_bb0360","doi-asserted-by":"crossref","first-page":"875","DOI":"10.1016\/j.autrev.2013.03.007","article-title":"The different roles of the thymus in the pathogenesis of the various myasthenia gravis subtypes","volume":"12","author":"Marx","year":"2013","journal-title":"Autoimmun. Rev."},{"key":"10.1016\/j.bbcan.2024.189145_bb0365","doi-asserted-by":"crossref","first-page":"13","DOI":"10.1186\/1746-1596-2-13","article-title":"Thymomas: a cytological and immunohistochemical study, with emphasis on lymphoid and neuroendocrine markers","volume":"2","author":"Alexiev","year":"2007","journal-title":"Diagn. Pathol."},{"key":"10.1016\/j.bbcan.2024.189145_bb0370","doi-asserted-by":"crossref","first-page":"34","DOI":"10.3389\/fneur.2017.00034","article-title":"B10 cell frequencies and suppressive capacity in myasthenia gravis are associated with disease severity","volume":"8","author":"Yi","year":"2017","journal-title":"Front. Neurol."},{"issue":"1","key":"10.1016\/j.bbcan.2024.189145_bb0375","doi-asserted-by":"crossref","first-page":"320","DOI":"10.1038\/s41392-023-01522-4","article-title":"Immune checkpoint therapy for solid tumours: clinical dilemmas and future trends","volume":"8","author":"Sun","year":"2023","journal-title":"Signal. Transduct. Target. Ther."},{"issue":"1","key":"10.1016\/j.bbcan.2024.189145_bb0380","doi-asserted-by":"crossref","first-page":"10","DOI":"10.1186\/s40164-023-00372-8","article-title":"Increasing cure rates of solid tumors by immune checkpoint inhibitors","volume":"12","author":"Ma","year":"2023","journal-title":"Exp. Hematol. Oncol."},{"key":"10.1016\/j.bbcan.2024.189145_bb0385","doi-asserted-by":"crossref","first-page":"550","DOI":"10.3389\/fimmu.2016.00550","article-title":"The PD1:PD-L1\/2 pathway from discovery to clinical implementation","volume":"7","author":"Bardhan","year":"2016","journal-title":"Front. Immunol."},{"issue":"3","key":"10.1016\/j.bbcan.2024.189145_bb0390","doi-asserted-by":"crossref","first-page":"500","DOI":"10.1097\/JTO.0000000000000429","article-title":"Diffuse high intensity PD-L1 staining in thymic epithelial tumors","volume":"10","author":"Padda","year":"2015","journal-title":"J. Thorac. Oncol."},{"issue":"8","key":"10.1016\/j.bbcan.2024.189145_bb0395","doi-asserted-by":"crossref","first-page":"1204","DOI":"10.1016\/j.jtho.2018.04.013","article-title":"Expression patterns, prognostic value, and Intratumoral heterogeneity of PD-L1 and PD-1 in Thymoma and Thymic carcinoma","volume":"13","author":"Owen","year":"2018","journal-title":"J. Thorac. Oncol."},{"issue":"2","key":"10.1016\/j.bbcan.2024.189145_bb0400","doi-asserted-by":"crossref","first-page":"154","DOI":"10.1016\/j.lungcan.2015.03.003","article-title":"Immunohistochemical status of PD-L1 in thymoma and thymic carcinoma","volume":"88","author":"Katsuya","year":"2015","journal-title":"Lung Cancer"},{"issue":"8","key":"10.1016\/j.bbcan.2024.189145_bb0405","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0182665","article-title":"Expression of PD-L1 and other immunotherapeutic targets in thymic epithelial tumors","volume":"12","author":"Arbour","year":"2017","journal-title":"PLoS One"},{"key":"10.1016\/j.bbcan.2024.189145_bb0410","doi-asserted-by":"crossref","first-page":"35","DOI":"10.1016\/j.lungcan.2018.09.002","article-title":"Different pattern of PD-L1, IDO, and FOXP3 Tregs expression with survival in thymoma and thymic carcinoma","volume":"125","author":"Wei","year":"2018","journal-title":"Lung Cancer"},{"issue":"11","key":"10.1016\/j.bbcan.2024.189145_bb0415","doi-asserted-by":"crossref","first-page":"1341","DOI":"10.1111\/1759-7714.12826","article-title":"Impact of PD-L1, transforming growth factor-\u03b2 expression and tumor-infiltrating CD8(+) T cells on clinical outcome of patients with advanced thymic epithelial tumors","volume":"9","author":"Duan","year":"2018","journal-title":"Thorac Cancer."},{"issue":"8","key":"10.1016\/j.bbcan.2024.189145_bb0420","doi-asserted-by":"crossref","first-page":"624","DOI":"10.1016\/j.it.2018.05.001","article-title":"Defining and understanding adaptive resistance in Cancer immunotherapy","volume":"39","author":"Kim","year":"2018","journal-title":"Trends Immunol."},{"issue":"9","key":"10.1016\/j.bbcan.2024.189145_bb0425","article-title":"Molecular predictors of response to pembrolizumab in thymic carcinoma","volume":"2","author":"He","year":"2021","journal-title":"Cell Rep. Med."},{"issue":"2","key":"10.1016\/j.bbcan.2024.189145_bb0430","doi-asserted-by":"crossref","first-page":"202","DOI":"10.1038\/s41588-018-0312-8","article-title":"Tumor mutational load predicts survival after immunotherapy across multiple cancer types","volume":"51","author":"Samstein","year":"2019","journal-title":"Nat. Genet."},{"issue":"11","key":"10.1016\/j.bbcan.2024.189145_bb0435","doi-asserted-by":"crossref","first-page":"2598","DOI":"10.1158\/1535-7163.MCT-17-0386","article-title":"Tumor mutational burden as an independent predictor of response to immunotherapy in diverse cancers","volume":"16","author":"Goodman","year":"2017","journal-title":"Mol. Cancer Ther."},{"issue":"11","key":"10.1016\/j.bbcan.2024.189145_bb0440","doi-asserted-by":"crossref","first-page":"919","DOI":"10.1093\/oncolo\/oyac115","article-title":"Comprehensive genomic profiling of 274 Thymic epithelial tumors unveils oncogenic pathways and predictive biomarkers","volume":"27","author":"Girard","year":"2022","journal-title":"Oncologist"},{"issue":"12","key":"10.1016\/j.bbcan.2024.189145_bb0445","doi-asserted-by":"crossref","first-page":"992","DOI":"10.1200\/JCO.18.01042","article-title":"First-line Nivolumab plus Ipilimumab in advanced non-small-cell lung Cancer (CheckMate 568): outcomes by programmed death ligand 1 and tumor mutational burden as biomarkers","volume":"37","author":"Ready","year":"2019","journal-title":"J. Clin. Oncol."},{"issue":"4","key":"10.1016\/j.bbcan.2024.189145_bb0450","doi-asserted-by":"crossref","first-page":"581","DOI":"10.1210\/er.2003-0027","article-title":"Vascular endothelial growth factor: basic science and clinical progress","volume":"25","author":"Ferrara","year":"2004","journal-title":"Endocr. Rev."},{"issue":"3","key":"10.1016\/j.bbcan.2024.189145_bb0455","doi-asserted-by":"crossref","first-page":"493","DOI":"10.1067\/mtc.2002.124389","article-title":"Correlation between tumor angiogenesis and invasiveness in thymic epithelial tumors","volume":"124","author":"Tomita","year":"2002","journal-title":"J. Thorac. Cardiovasc. Surg."},{"issue":"9","key":"10.1016\/j.bbcan.2024.189145_bb0460","doi-asserted-by":"crossref","first-page":"3597","DOI":"10.1182\/blood-2002-07-2307","article-title":"SU11248 is a novel FLT3 tyrosine kinase inhibitor with potent activity in vitro and in vivo","volume":"101","author":"O\u2019Farrell","year":"2003","journal-title":"Blood"},{"issue":"2","key":"10.1016\/j.bbcan.2024.189145_bb0465","doi-asserted-by":"crossref","first-page":"177","DOI":"10.1016\/S1470-2045(14)71181-7","article-title":"Sunitinib in patients with chemotherapy-refractory thymoma and thymic carcinoma: an open-label phase 2 trial","volume":"16","author":"Thomas","year":"2015","journal-title":"Lancet Oncol."},{"issue":"1","key":"10.1016\/j.bbcan.2024.189145_bb0470","doi-asserted-by":"crossref","first-page":"S313","DOI":"10.1016\/j.jtho.2016.11.332","article-title":"OA18.02 evaluation of a modified dosing regimen (2-weeks on\/1-week off) of Sunitinib as part of a phase II trial in Thymic carcinoma","volume":"12","author":"Rajan","year":"2017","journal-title":"J. Thorac. Oncol."},{"issue":"10","key":"10.1016\/j.bbcan.2024.189145_bb0475","doi-asserted-by":"crossref","first-page":"S346","DOI":"10.1016\/j.jtho.2018.08.297","article-title":"OA11.05 phase II study of Sunitinib in patients with Thymic carcinoma previously treated with platinum-based chemotherapy (KOSMIC trial)","volume":"13","author":"Kim","year":"2018","journal-title":"J. Thorac. Oncol."},{"issue":"7","key":"10.1016\/j.bbcan.2024.189145_bb0480","doi-asserted-by":"crossref","first-page":"621","DOI":"10.1056\/NEJMoa1406470","article-title":"Lenvatinib versus placebo in radioiodine-refractory thyroid cancer","volume":"372","author":"Schlumberger","year":"2015","journal-title":"N. Engl. J. Med."},{"issue":"4","key":"10.1016\/j.bbcan.2024.189145_bb0485","doi-asserted-by":"crossref","first-page":"512","DOI":"10.1007\/s00535-016-1263-4","article-title":"Phase 2 study of lenvatinib in patients with advanced hepatocellular carcinoma","volume":"52","author":"Ikeda","year":"2017","journal-title":"J. Gastroenterol."},{"issue":"4","key":"10.1016\/j.bbcan.2024.189145_bb0490","doi-asserted-by":"crossref","first-page":"719","DOI":"10.1002\/cncr.33990","article-title":"Resound trial: a phase 2 study of regorafenib in patients with thymoma (type B2-B3) and thymic carcinoma previously treated with chemotherapy","volume":"128","author":"Perrino","year":"2022","journal-title":"Cancer"},{"issue":"1","key":"10.1016\/j.bbcan.2024.189145_bb0495","doi-asserted-by":"crossref","first-page":"154","DOI":"10.1186\/s12916-022-02361-w","article-title":"Apatinib in patients with recurrent or metastatic thymic epithelial tumor: a single-arm, multicenter, open-label, phase II trial","volume":"20","author":"Song","year":"2022","journal-title":"BMC Med."},{"issue":"16_suppl","key":"10.1016\/j.bbcan.2024.189145_bb0500","article-title":"KC1036, a novel oral multi-kinase inhibitor, in patients with previously treated advanced esophageal squamous cell carcinoma (ESCC): results from a multicenter, single-arm phase II trial","volume":"41","author":"Zhang","year":"2023","journal-title":"J. Clin. Oncol."},{"issue":"7","key":"10.1016\/j.bbcan.2024.189145_bb0505","doi-asserted-by":"crossref","first-page":"637","DOI":"10.1136\/jclinpath-2017-204788","article-title":"PD-1 and PD-L1 expression in thymic epithelial tumours and non-neoplastic thymus","volume":"71","author":"Bagir","year":"2018","journal-title":"J. Clin. Pathol."},{"issue":"6","key":"10.1016\/j.bbcan.2024.189145_bb0510","doi-asserted-by":"crossref","first-page":"826","DOI":"10.1038\/modpathol.2017.6","article-title":"Expression of PD-1 and PD-L1 in thymic epithelial neoplasms","volume":"30","author":"Weissferdt","year":"2017","journal-title":"Mod. Pathol."},{"issue":"3","key":"10.1016\/j.bbcan.2024.189145_bb0515","doi-asserted-by":"crossref","first-page":"483","DOI":"10.1016\/j.jtho.2020.11.003","article-title":"Durable response in patients with Thymic carcinoma treated with Pembrolizumab after prolonged follow-up","volume":"16","author":"Giaccone","year":"2021","journal-title":"J. Thorac. Oncol."},{"issue":"3","key":"10.1016\/j.bbcan.2024.189145_bb0520","doi-asserted-by":"crossref","first-page":"347","DOI":"10.1016\/S1470-2045(18)30062-7","article-title":"Pembrolizumab in patients with thymic carcinoma: a single-arm, single-Centre, phase 2 study","volume":"19","author":"Giaccone","year":"2018","journal-title":"Lancet Oncol."},{"issue":"24","key":"10.1016\/j.bbcan.2024.189145_bb0525","doi-asserted-by":"crossref","first-page":"2162","DOI":"10.1200\/JCO.2017.77.3184","article-title":"Pembrolizumab for patients with refractory or relapsed Thymic epithelial tumor: an open-label phase II trial","volume":"37","author":"Cho","year":"2019","journal-title":"J. Clin. Oncol."},{"issue":"1","key":"10.1016\/j.bbcan.2024.189145_bb0530","doi-asserted-by":"crossref","first-page":"269","DOI":"10.1186\/s40425-019-0723-9","article-title":"Efficacy and tolerability of anti-programmed death-ligand 1 (PD-L1) antibody (Avelumab) treatment in advanced thymoma","volume":"7","author":"Rajan","year":"2019","journal-title":"J. Immunother. Cancer"},{"issue":"2","key":"10.1016\/j.bbcan.2024.189145_bb0535","doi-asserted-by":"crossref","DOI":"10.1016\/j.esmoop.2022.100419","article-title":"Phase II multicohort study of atezolizumab monotherapy in multiple advanced solid cancers","volume":"7","author":"Tabernero","year":"2022","journal-title":"ESMO Open."},{"key":"10.1016\/j.bbcan.2024.189145_bb0540","doi-asserted-by":"crossref","first-page":"78","DOI":"10.1016\/j.ejca.2019.03.012","article-title":"Single-arm, multicentre, phase II trial of nivolumab for unresectable or recurrent thymic carcinoma: PRIMER study","volume":"113","author":"Katsuya","year":"2019","journal-title":"Eur. J. Cancer"},{"issue":"3","key":"10.1016\/j.bbcan.2024.189145_bb0545","doi-asserted-by":"crossref","DOI":"10.1016\/j.esmoop.2023.101576","article-title":"Efficacy and safety of nivolumab for patients with pre-treated type B3 thymoma and thymic carcinoma: results from the EORTC-ETOP NIVOTHYM phase II trial","volume":"8","author":"Girard","year":"2023","journal-title":"ESMO Open."},{"issue":"12","key":"10.1016\/j.bbcan.2024.189145_bb0550","doi-asserted-by":"crossref","first-page":"3100","DOI":"10.1038\/s41591-023-02591-2","article-title":"Thymus alterations and susceptibility to immune checkpoint inhibitor myocarditis","volume":"29","author":"Fenioux","year":"2023","journal-title":"Nat. Med."},{"issue":"11","key":"10.1016\/j.bbcan.2024.189145_bb0555","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0007669","article-title":"Cytokine levels correlate with immune cell infiltration after anti-VEGF therapy in preclinical mouse models of breast cancer","volume":"4","author":"Roland","year":"2009","journal-title":"PLoS One"},{"issue":"5","key":"10.1016\/j.bbcan.2024.189145_bb0560","doi-asserted-by":"crossref","first-page":"325","DOI":"10.1038\/nrclinonc.2018.29","article-title":"Enhancing cancer immunotherapy using antiangiogenics: opportunities and challenges","volume":"15","author":"Fukumura","year":"2018","journal-title":"Nat. Rev. Clin. Oncol."},{"issue":"12","key":"10.1016\/j.bbcan.2024.189145_bb0565","doi-asserted-by":"crossref","first-page":"1103","DOI":"10.1056\/NEJMoa1816047","article-title":"Avelumab plus Axitinib versus Sunitinib for advanced renal-cell carcinoma","volume":"380","author":"Motzer","year":"2019","journal-title":"N. Engl. J. Med."},{"issue":"2","key":"10.1016\/j.bbcan.2024.189145_bb0570","article-title":"A phase 1\/2 study to evaluate the safety and activity of Nivolumab in combination with Vorolanib, a vascular endothelial growth factor tyrosine kinase inhibitor, in patients with refractory thoracic tumors","volume":"5","author":"Beckermann","year":"2024","journal-title":"JTO Clin. Res. Rep."},{"issue":"15","key":"10.1016\/j.bbcan.2024.189145_bb0575","doi-asserted-by":"crossref","first-page":"2060","DOI":"10.1200\/JCO.2010.32.9607","article-title":"Phase II study of carboplatin and paclitaxel in advanced thymoma and thymic carcinoma","volume":"29","author":"Lemma","year":"2011","journal-title":"J. Clin. Oncol."},{"issue":"2","key":"10.1016\/j.bbcan.2024.189145_bb0580","doi-asserted-by":"crossref","first-page":"363","DOI":"10.1093\/annonc\/mdu541","article-title":"A multicenter phase II study of carboplatin and paclitaxel for advanced thymic carcinoma: WJOG4207L","volume":"26","author":"Hirai","year":"2015","journal-title":"Ann. Oncol."},{"issue":"3","key":"10.1016\/j.bbcan.2024.189145_bb0585","doi-asserted-by":"crossref","first-page":"143","DOI":"10.1038\/nrclinonc.2015.209","article-title":"Combination cancer immunotherapies tailored to the tumour microenvironment","volume":"13","author":"Smyth","year":"2016","journal-title":"Nat. Rev. Clin. Oncol."},{"issue":"1","key":"10.1016\/j.bbcan.2024.189145_bb0590","doi-asserted-by":"crossref","first-page":"60","DOI":"10.1186\/s12943-019-0974-6","article-title":"Synergistic effect of immune checkpoint blockade and anti-angiogenesis in cancer treatment","volume":"18","author":"Yi","year":"2019","journal-title":"Mol. Cancer"},{"key":"10.1016\/j.bbcan.2024.189145_bb0595","doi-asserted-by":"crossref","first-page":"66","DOI":"10.1016\/j.canlet.2019.02.048","article-title":"Mechanisms and therapeutic potentials of cancer immunotherapy in combination with radiotherapy and\/or chemotherapy","volume":"452","author":"Yu","year":"2019","journal-title":"Cancer Lett."},{"issue":"10278","key":"10.1016\/j.bbcan.2024.189145_bb0600","doi-asserted-by":"crossref","first-page":"1010","DOI":"10.1016\/S0140-6736(20)32598-8","article-title":"Enhancing anti-tumour efficacy with immunotherapy combinations","volume":"397","author":"Meric-Bernstam","year":"2021","journal-title":"Lancet"},{"issue":"4","key":"10.1016\/j.bbcan.2024.189145_bb0605","doi-asserted-by":"crossref","first-page":"263","DOI":"10.1007\/s12272-022-01382-6","article-title":"Anti-angiogenesis revisited: reshaping the treatment landscape of advanced non-small cell lung cancer","volume":"45","author":"Choi","year":"2022","journal-title":"Arch. Pharm. Res."},{"issue":"7","key":"10.1016\/j.bbcan.2024.189145_bb0610","doi-asserted-by":"crossref","first-page":"e247","DOI":"10.1016\/j.cllc.2023.05.004","article-title":"Study design and rationale for marble study: a phase II trial of Atezolizumab (MPDL3280A) plus carboplatin and paclitaxel in patients with advanced or recurrent Thymic carcinoma (JTD2101)","volume":"24","author":"Asao","year":"2023","journal-title":"Clin. Lung Cancer"},{"issue":"4","key":"10.1016\/j.bbcan.2024.189145_bb0615","doi-asserted-by":"crossref","first-page":"389","DOI":"10.1016\/j.cllc.2024.02.002","article-title":"Artemis: a multicenter, open-label, single-arm, phase II study to evaluate the efficacy and safety of first-line carboplatin\/paclitaxel\/Lenvatinib\/Pembrolizumab combination for previously untreated advanced or recurrent Thymic carcinomas","volume":"25","author":"Okuma","year":"2024","journal-title":"Clin. Lung Cancer."},{"issue":"3","key":"10.1016\/j.bbcan.2024.189145_bb0620","doi-asserted-by":"crossref","first-page":"315","DOI":"10.1001\/jamaoncol.2023.5258","article-title":"Atezolizumab and platinum plus Pemetrexed with or without bevacizumab for metastatic nonsquamous non-small cell lung Cancer: a phase 3 randomized clinical trial","volume":"10","author":"Shiraishi","year":"2024","journal-title":"JAMA Oncol."},{"issue":"11","key":"10.1016\/j.bbcan.2024.189145_bb0625","doi-asserted-by":"crossref","first-page":"S44","DOI":"10.1016\/j.jtho.2023.09.024","article-title":"OA01.03 Benmelstobart with Anlotinib plus chemotherapy as first-line therapy for ES-SCLC: a randomized, double-blind, phase III trial","volume":"18","author":"Cheng","year":"2023","journal-title":"J. Thorac. Oncol."},{"issue":"1","key":"10.1016\/j.bbcan.2024.189145_bb0630","doi-asserted-by":"crossref","first-page":"3","DOI":"10.1002\/cac2.12517","article-title":"Development of antibody-drug conjugates in cancer: overview and prospects","volume":"44","author":"Ruan","year":"2024","journal-title":"Cancer Commun. (Lond)."},{"issue":"1","key":"10.1016\/j.bbcan.2024.189145_bb0635","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1186\/s13045-023-01509-2","article-title":"The promise and challenges of combination therapies with antibody-drug conjugates in solid tumors","volume":"17","author":"Wei","year":"2024","journal-title":"J. Hematol. Oncol."},{"key":"10.1016\/j.bbcan.2024.189145_bb0640","doi-asserted-by":"crossref","first-page":"31","DOI":"10.1146\/annurev-med-071322-065903","article-title":"Leveraging TROP2 antibody-drug conjugates in solid tumors","volume":"75","author":"Nelson","year":"2024","journal-title":"Annu. Rev. Med."},{"key":"10.1016\/j.bbcan.2024.189145_bb0645","doi-asserted-by":"crossref","DOI":"10.1016\/j.lungcan.2023.107324","article-title":"High levels of expression of Trop-2 in thymic epithelial tumors","volume":"184","author":"Yeung","year":"2023","journal-title":"Lung Cancer"},{"issue":"2","key":"10.1016\/j.bbcan.2024.189145_bb0650","doi-asserted-by":"crossref","first-page":"180","DOI":"10.1016\/j.cllc.2024.01.001","article-title":"Trop-2 expression and its impact on survival in Thymic epithelial tumors: brief report","volume":"25","author":"Ardeshir-Larijani","year":"2024","journal-title":"Clin. Lung Cancer"},{"issue":"16","key":"10.1016\/j.bbcan.2024.189145_bb0655","doi-asserted-by":"crossref","first-page":"1529","DOI":"10.1056\/NEJMoa2028485","article-title":"Sacituzumab Govitecan in metastatic triple-negative breast Cancer","volume":"384","author":"Bardia","year":"2021","journal-title":"N. Engl. J. Med."},{"issue":"4","key":"10.1016\/j.bbcan.2024.189145_bb0660","doi-asserted-by":"crossref","first-page":"392","DOI":"10.1016\/j.annonc.2024.01.002","article-title":"TROPHY-U-01, a phase II open-label study of sacituzumab govitecan in patients with metastatic urothelial carcinoma progressing after platinum-based chemotherapy and checkpoint inhibitors: updated safety and efficacy outcomes","volume":"35","author":"Loriot","year":"2024","journal-title":"Ann. Oncol."},{"issue":"1","key":"10.1016\/j.bbcan.2024.189145_bb0665","doi-asserted-by":"crossref","first-page":"1721810","DOI":"10.1080\/2162402X.2020.1721810","article-title":"PT-112 induces immunogenic cell death and synergizes with immune checkpoint blockers in mouse tumor models","volume":"9","author":"Yamazaki","year":"2020","journal-title":"Oncoimmunology"},{"key":"10.1016\/j.bbcan.2024.189145_bb0670","doi-asserted-by":"crossref","DOI":"10.1016\/j.eclinm.2022.101430","article-title":"Phase I study of PT-112, a novel pyrophosphate-platinum immunogenic cell death inducer, in advanced solid tumours","volume":"49","author":"Karp","year":"2022","journal-title":"EClinicalMedicine"},{"issue":"11","key":"10.1016\/j.bbcan.2024.189145_bb0675","doi-asserted-by":"crossref","first-page":"2117","DOI":"10.1002\/1878-0261.13146","article-title":"Dual inhibition of TGF-beta and PD-L1: a novel approach to cancer treatment","volume":"16","author":"Gulley","year":"2022","journal-title":"Mol. Oncol."},{"issue":"9","key":"10.1016\/j.bbcan.2024.189145_bb0680","doi-asserted-by":"crossref","DOI":"10.1172\/jci.insight.85974","article-title":"TGF-\u03b2 and VEGF cooperatively control the immunotolerant tumor environment and the efficacy of cancer immunotherapies","volume":"1","author":"Courau","year":"2016","journal-title":"JCI Insight"},{"issue":"4","key":"10.1016\/j.bbcan.2024.189145_bb0685","doi-asserted-by":"crossref","first-page":"237","DOI":"10.1038\/s41571-021-00588-9","article-title":"Harnessing cytokines and chemokines for cancer therapy","volume":"19","author":"Propper","year":"2022","journal-title":"Nat. Rev. Clin. Oncol."},{"key":"10.1016\/j.bbcan.2024.189145_bb0690","doi-asserted-by":"crossref","DOI":"10.1016\/j.intimp.2024.112156","article-title":"IL-15 as a key regulator in NK cell-mediated immunotherapy for cancer: from bench to bedside","volume":"133","author":"Vahidi","year":"2024","journal-title":"Int. Immunopharmacol."},{"issue":"12","key":"10.1016\/j.bbcan.2024.189145_bb0695","doi-asserted-by":"crossref","first-page":"731","DOI":"10.1038\/s41571-018-0113-0","article-title":"NTRK fusion-positive cancers and TRK inhibitor therapy","volume":"15","author":"Cocco","year":"2018","journal-title":"Nat. Rev. Clin. Oncol."},{"issue":"4","key":"10.1016\/j.bbcan.2024.189145_bb0700","doi-asserted-by":"crossref","first-page":"611","DOI":"10.1016\/j.ejcts.2005.06.034","article-title":"Expression of neurotrophin receptors in surgically resected thymic epithelial tumors","volume":"28","author":"Kim","year":"2005","journal-title":"Eur. J. Cardiothorac. Surg."},{"issue":"36","key":"10.1016\/j.bbcan.2024.189145_bb0705","doi-asserted-by":"crossref","first-page":"4820","DOI":"10.1200\/JCO.2011.36.0487","article-title":"Thymic malignancies: from clinical management to targeted therapies","volume":"29","author":"Kelly","year":"2011","journal-title":"J. Clin. Oncol."},{"issue":"12","key":"10.1016\/j.bbcan.2024.189145_bb0710","article-title":"The first reported case of neurotrophic tyrosine receptor kinase fusion-positive Thymoma treated successfully with Entrectinib","volume":"13","author":"Salame","year":"2021","journal-title":"Cureus"},{"issue":"15_suppl","key":"10.1016\/j.bbcan.2024.189145_bb0715","doi-asserted-by":"crossref","first-page":"3081","DOI":"10.1200\/JCO.2021.39.15_suppl.3081","article-title":"First-time in-human study of VMD-928, an oral allosteric TrkA selective inhibitor targeting TrkA protein overexpression, in patients with solid tumors or lymphoma","volume":"39","author":"Chung","year":"2021","journal-title":"J. Clin. Oncol."}],"container-title":["Biochimica et Biophysica Acta (BBA) - Reviews on Cancer"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0304419X24000763?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0304419X24000763?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,1,22]],"date-time":"2025-01-22T23:12:00Z","timestamp":1737587520000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0304419X24000763"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,9]]},"references-count":143,"journal-issue":{"issue":"5","published-print":{"date-parts":[[2024,9]]}},"alternative-id":["S0304419X24000763"],"URL":"https:\/\/doi.org\/10.1016\/j.bbcan.2024.189145","relation":{},"ISSN":["0304-419X"],"issn-type":[{"value":"0304-419X","type":"print"}],"subject":[],"published":{"date-parts":[[2024,9]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Evolving treatment landscape in thymic epithelial tumors: From mechanism to therapy","name":"articletitle","label":"Article Title"},{"value":"Biochimica et Biophysica Acta (BBA) - Reviews on Cancer","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.bbcan.2024.189145","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2024 The Author(s). Published by Elsevier B.V.","name":"copyright","label":"Copyright"}],"article-number":"189145"}}